N-(4,6-DIMETHOXY-1,3,5-TRIAZIN-2-YLCARBAMOYL)-4-((2-FLUOROETHOXY)METHYL)THIAZOLE-5-SULFONAMIDE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	UVXUCXUEGTWCQM-UHFFFAOYSA-N
Smiles	COc1nc(NC(=O)NS(=O)(=O)c2scnc2COCCF)nc(OC)n1
InChI	InChI=1S/C12H15FN6O6S2/c1-23-11-16-9(17-12(18-11)24-2)15-10(20)19-27(21,22)8-7(14-6-26-8)5-25-4-3-13/h6H,3-5H2,1-2H3,(H2,15,16,17,18,19,20)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C12H15FN6O6S2
Molecular Weight	422.41
AlogP	0.74
Hydrogen Bond Acceptor	10.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	9.0
Polar Surface Area	191.13
Molecular species	ACID
Aromatic Rings	2.0
Heavy Atoms	27.0

Assay Description	Organism	Bioactivity
Toxicity in two leaf stage of Oryza sativa var. Nihonbare (rice) assessed as dose required to selectivity to Oryza sativa	Oryza sativa	2.5 g/acre
Herbicidal activity against Sagittaria pygmaea assessed as dose required to cause sufficient herbicidal activity after 5 to 7 days	Sagittaria pygmaea	2.5 g/acre
Herbicidal activity against Echinochloa oryzicola assessed as dose required to cause sufficient herbicidal activity	Echinochloa oryzicola	2.5 g/acre
Herbicidal activity against Schoenoplectiella juncoides assessed as dose required to cause sufficient herbicidal activity after 5 to 7 days	Schoenoplectiella juncoides	2.5 g/acre

Cross References

Resources	Reference
ChEMBL	CHEMBL2286313
PubChem	76323724

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).